Is Oxyntomodulin FDA approved?

Oxyntomodulin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

How is Oxyntomodulin administered in research settings?

In research settings, Oxyntomodulin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Oxyntomodulin vs Pramlintide

Peptide Comparison

Oxyntomodulin vs Pramlintide

Q: What is the difference between Oxyntomodulin and Pramlintide?

Oxyntomodulin: Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate. Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Both are Metabolic peptides.

Oxyntomodulin

OXM

Fat LossInvestigationalResearch Only

No providers listed yet

Full Oxyntomodulin profile →

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Bottom line

Pramlintide is FDA-approved, while Oxyntomodulin is investigational — the clearest structural difference between them.

Quick Verdict

Oxyntomodulin

Half-life

—

Pramlintide

Half-life

~48 minutes

Which One Should You Choose?

Your goal	Better option
Further along in FDA review	Pramlintide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Oxyntomodulin

Pramlintide

Mechanism Family

Metabolic

Half-life

—

~48 minutes

FDA Status

investigational

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

None listed

FDA Update

—

Mar 2005

Avail. Notes

—

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Research Evidence

Oxyntomodulin

RCT · 4 key studies · most recent 2026

Pramlintide

RCT · 3 key studies · most recent 2026

Research Citations

Oxyntomodulin

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2005 · Diabetes

Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects

Review2026 · Expert Opin Ther Pat

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…

Review2026 · Endocr Rev

Regulators of Appetite in Mammals - Old and New players.

Pramlintide

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

In vitro2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Research Areas

appetite suppressionenergy expenditurefat oxidation

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Oxyntomodulin

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Oxyntomodulin

Browse directory →

Providers offering

Pramlintide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.